1163 – Testing for gastric cancer for access to trastuzumab

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Deferred

Application details

Reason for application

New MBS item.

Service or technology in this application

In-situ hybridisation (ISH) for PBS listing of trastuzumab.

Type: Investigative

Medical condition this application addresses

Previously untreated human epidermal growth factor receptor 2 (HER2) positive inoperable locally advanced or metastatic gastric or gastro-oesophageal cancer.

Meetings to consider this application

  • PASC meeting: 7 July 2011
  • ESC meeting: 11 - 12 October 2012
  • MSAC meeting: 29 - 30 November 2012